Role of dopamine D 3 and serotonin 5-HT 1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine- lesioned rat model of Parkinson's disease

Journal of Neural Transmission

Volumn 118, Issue 12, 2011, Pages 1733-1742

  Gerlach, Manfred ^a   Bartoszyk, Gerd D ^b   Riederer, Peter ^a   Dean, Olivia ^c   Van Den Buuse, Maarten ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Merck Serono GmbH   (Germany)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Abnormal involuntary movements; Dopamine D 3 receptors; l DOPA induced dyskinesia; Parkinson therapy; Sarizotan; Serotonin 5 HT 1A receptors

Indexed keywords

3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 4' ACETYL N [4 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]BUTYL]BIPHENYL 4 CARBOXAMIDE; BENSERAZIDE; DOPAMINE 3 RECEPTOR; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXIDOPAMINE; SARIZOTAN; SEROTONIN 1A RECEPTOR; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ORGANIC COMPOUND; SEROTONIN 1 AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSKINESIA; DYSTONIA; MALE; NONHUMAN; PARKINSON DISEASE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ADMINISTRATION; DRUG INTERACTION; METABOLISM; PARKINSONISM; SPRAGUE DAWLEY RAT; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; ORGANIC CHEMICALS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D3; SEROTONIN 5-HT1 RECEPTOR AGONISTS; TIME FACTORS;

EID: 84855192614     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0571-8     Document Type: Article

References (54)

1. S Ahlenius I Henriksson O Magnusson P Salmi 1999 In vivo intrinsic efficacy of the 5-HT1A receptor antagonists NAD-299, WAY-100, 635 and (S)-(-)-UH-301 at rat brain monoamine receptors Eur Neuropsychopharmacol 9 15 19 10082223 10.1016/S0924-977X(97)00100-4 1:CAS:528:DyaK1MXksFCmsw%3D%3D (Pubitemid 29073678)
2. T Antonelli K Fuxe MC Tomasini GD Bartoszyk CA Seyfried S Tanganelli L Ferraro 2005 Effects of sarizotan on the corticostriatal glutamate pathways Synapse 58 193 199 16138317 10.1002/syn.20195 1:CAS:528:DC%2BD2MXhtFensrbI (Pubitemid 41443739)
3. R Arai K Horiike Y Hasegawa 1998 Dopamine-degrading activity of monoamine oxidase in locus coeruleus and dorsal raphe nucleus neurons. A histochemical study in the rat Neurosci Lett 250 41 44 9696061 10.1016/S0304-3940(98)00429-7 1:CAS:528:DyaK1cXjvFOgsbo%3D (Pubitemid 28341772)
4. V Audinot A Newman-Tancredi A Gobert JM Rivet M Brocco F Lejeune L Gluck I Desposte K Bervoets A Dekeyne MJ Millan 1998 A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D-3 receptor antagonists (+)-S 14297, nafadotride, GR 103, 691 and U 99194 J Pharmacol Exp Ther 287 187 197 9765337 1:CAS:528:DyaK1cXmvVSqur4%3D (Pubitemid 29140201)
5. MW Ba M Kong GZ Ma HQ Yang GQ Lu SD Chen ZG Liu 2007 Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications Brain Res 1127 177 184 17113046 10.1016/j.brainres.2006.10.020 1:CAS:528:DC%2BD28Xht12msb3E (Pubitemid 44854850)
6. W Bara-Jimenez F Bibbiani MJ Morns T Dimitrova A Sherzai MM Mouradian T Chase 2005 Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease Mov Disord 20 932 936 15791634 10.1002/mds.20370 (Pubitemid 41419506)
7. GD Bartoszyk C van Amsterdam HE Greiner W Rautenberg H Russ CA Seyfried 2004 Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile J Neural Transm 111 113 126 14767715 10.1007/s00702-003-0094-7 1:CAS:528:DC%2BD2cXhtVOlsLw%3D (Pubitemid 38283223)
8. F Bibbiani JD Oh TN Chase 2001 Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 57 1829 1834 11723272 1:CAS:528:DC%2BD38XjvVI%3D (Pubitemid 33096691)
9. C Bishop JL Taylor DM Kuhn KL Eskow JY Park PD Walker 2006 MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation Eur J Neurosci 23 2669 2676 16817869 10.1111/j.1460-9568.2006.04790. x (Pubitemid 43801458)
10. R Bordet S Ridray S Carbon J Diaz P Sokoloff JC Schwartz 1997 Induction of dopamine D-3 receptor expression as a mechanism of behavioral sensitization to levodopa Proc Natl Acad Sci USA 94 3363 3367 9096399 10.1073/pnas.94.7.3363 1:CAS:528:DyaK2sXisVKnsrg%3D (Pubitemid 27157317)
11. JA Brotchie 2005 Nondopaminergic mechanisms in levodopa-induced dyskinesia Mov Disord 20 919 931 16007614 10.1002/mds.20612 (Pubitemid 41419505)
12. RJ Carey 1991 Chronic l-dopa treatment in the unilateral 6-OHDA rat-evidence for behavioral sensitization and biochemical tolerance Brain Res 568 205 214 1814568 10.1016/0006-8993(91)91399-L 1:CAS:528:DyaK38XpvFWrug%3D%3D
13. M Carta M Carlsson D Kirik A Björklund 2007 Dopamine released from 5-HT terminals is the cause of l-dopa-induced dyskinesia in parkinsonian rats Brain 130 1819 1833 17452372 10.1093/brain/awm082 (Pubitemid 47343795)
14. E Castaneda S Fleming MA Paquette K Boat J Moffett EK Stachowiak DC Bloom MK Stachowiak 2005 Assessment of recovery in the hemiparkinson rat: drug-induced rotation is inadequate Physiol Behav 84 525 535 15811387 10.1016/j.physbeh.2005.01.019 1:CAS:528:DC%2BD2MXivFyqsrw%3D (Pubitemid 40487471)
15. MA Cenci 2007 Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia Trends Neurosci 30 236 243 17400300 10.1016/j.tins.2007.03.005 1:CAS:528:DC%2BD2sXkslent7s%3D (Pubitemid 46654236)
16. MA Cenci CS Lee A Björklund 1998 l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur J Neurosci 10 2694 2706 9767399 10.1046/j.1460-9568. 1998.00285.x 1:STN:280:DyaK1M7ksFKrsA%3D%3D (Pubitemid 28362576)
17. DR Cooper C Marrel B Testa H van de Waterbeemd N Quinn P Jenner CD Marsden 1984 l-Dopa methyl ester: a candidate for chronic systemic delivery of l-Dopa in Parkinson's disease Clin Neuropharmacol 7 89 98 6704979 10.1097/00002826-198403000-00005 1:CAS:528:DyaL2cXhs1yitbg%3D (Pubitemid 14138570)
18. SA Daly JL Waddington 1993 Behavioral effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other D-2-like agonists Neuropharmacology 32 509 510 8321432 10.1016/0028-3908(93)90177-5 1:CAS:528:DyaK3sXksVWlsLw%3D (Pubitemid 23161562)
19. A Dekundy M Lundblad W Danysz MA Cenci 2007 Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model Behav Brain Res 179 76 89 17306893 10.1016/j.bbr.2007.01.013 1:CAS:528:DC%2BD2sXjsVegur8%3D (Pubitemid 46441485)
20. KB Dupre KL Eskow B Negron C Bishop 2007 The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rats Brain Res 1158 135 143 17553470 10.1016/j.brainres.2007.05.005 1:CAS:528:DC%2BD2sXotVWltrk%3D (Pubitemid 47068412)
21. KL Eskow KB Dupre CJ Barnum SO Dickinson JY Park C Bishop 2009 The role of the dorsal raphe nucleus in the development, expression, and treatment of l-dopa-induced dyskinesia in hemiparkinsonian rats Synapse 63 610 620 19309758 10.1002/syn.20630 1:CAS:528:DC%2BD1MXmsFSqu7w%3D
22. SH Fox AE Lang JM Brotchie 2006 Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase Ila clinical studies: keys to success and roads to failure Mov Disord 21 1578 1594 16874752 10.1002/mds.20936 (Pubitemid 44742184)
23. 1A agonist, in 6-hydroxydopamine- lesioned rat Psychopharmacology (Berlin) 94 178 182
24. M Gerlach P Riederer 1996 Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man J Neural Transm 103 987 1041 9013391 10.1007/BF01291788 1:CAS:528:DyaK28XntVKku7Y%3D (Pubitemid 26383833)
25. M Gerlach M van den Buuse C Blaha D Bremen P Riederer 2004 Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine- lesioned rat Naunyn Schmiedeberg's Arch Pharmacol 370 388 394 10.1007/s00210-004-0984-8 1:CAS:528:DC%2BD2cXps1Wqurs%3D (Pubitemid 40022459)
26. CG Goetz P Damier C Hicking E Laska T Müller CW Olanow O Rascol H Russ 2007 Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov Disord 22 179 186 17094088 10.1002/mds.21226 (Pubitemid 46374758)
27. L Grégoire P Samadi J Graham PJ Bédard GD Bartoszyk T Di Paolo 2009 Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-DOPA in parkinsonian monkeys Parkinsonism Relat Disord 15 445 452 19196540 10.1016/j.parkreldis.2008.11.001
28. B Henry AR Crossman JM Brotchie 1999 Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat Exp Neurol 155 204 220 10072296 10.1006/exnr.1998.6996 1:CAS:528: DyaK1MXhs1Smu7o%3D (Pubitemid 29124714)
29. A Holmes JE Lachowicz DR Sibley 2004 Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes Neuropharmacology 47 1117 1134 15567422 10.1016/j.neuropharm.2004.07.034 1:CAS:528:DC%2BD2cXhtVahurfM (Pubitemid 39572704)
30. A Hsu DM Togasaki E Bezard P Sokoloff JW Langston DA Di Monte M Quik 2004 Effect of the D3 dopamine receptor partial agonist BP897N-4-(4-(2- methoxyphenyl)piperazinyl)butyl-2-naphthamide on l-3,4-dihydroxyphenylalanine- induced dyskinesias and parkinsonism in squirrel monkeys J Pharmacol Exp Ther 311 770 777 15226382 10.1124/jpet.104.071142 1:CAS:528:DC%2BD2cXptVKru7g%3D (Pubitemid 39391566)
31. MM Iravani MJ Jackson M Kuoppamaki LA Smith P Jenner 2003 3,4-Methylene-dioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates J Neurosci 23 9107 9115 14534244 1:CAS:528:DC%2BD2cXhvF2isb0%3D (Pubitemid 37243811)
32. JJ Jankovic 2005 Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations Mov Disord 20 Suppl 11 S11 S16 15822109 10.1002/mds.20458 (Pubitemid 40846906)
33. P Jenner 2008 Molecular mechanisms of l-DOPA-induced dyskinesia Nat Rev Neurosci 9 665 677 18714325 10.1038/nrn2471 1:CAS:528:DC%2BD1cXhtVSjurvP
34. RM Kostrzewa JP Kostrzewa P Nowak RA Kostrzewa R Brus 2004 Dopamine D-2 agonist priming in intact and dopamine-lesioned rats Neurotoxicol Res 6 457 462 10.1007/BF03033281
35. EL Lane SC Cheetham P Jenner 2006 Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp Neurol 197 284 290 16005456 10.1016/j.expneurol.2005.06.006 1:CAS:528:DC%2BD28XksVKgsQ%3D%3D (Pubitemid 43077136)
36. D Lévesque J Diaz C Pilon MP Martres B Giro E Souil D Schott JL Morgat JC Schwartz P Sokoloff 1992 Identification, characterization, and localization of the dopamine-D3 receptor in rat brain using 7-[3H]hydroxy-N,N- di-normal-propyl-2-aminotetralin Proc Natl Acad Sci USA 89 8155 8159 1518841 10.1073/pnas.89.17.8155
37. M Lundblad M Andersson C Winkler D Kirik N Wierup MA Cenci 2002 Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur J Neurosci 15 120 132 11860512 10.1046/j.0953-816x.2001.01843.x 1:STN:280:DC%2BD387ktFynug%3D%3D (Pubitemid 35478015)
38. M Lundblad B Picconi H Lindgren MA Cenci 2004 A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function Neurobiol Dis 16 110 123 15207268 10.1016/j.nbd.2004.01.007 1:CAS:528:DC%2BD2cXjs1altbw%3D (Pubitemid 38569802)
39. C Marin E Aguilar MC Rodrígues-Oroz GD Bartoszyk JA Obeso 2009 Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats Psychopharmacology 204 241 250 19159919 10.1007/s00213-008-1452-9 1:CAS:528:DC%2BD1MXpt1Gmug%3D%3D
40. K Matsubara K Shimizu M Suno K Ogawa T Awaya T Yamada T Noda M Satomi K Ohtaki K Chiba Y Tasaki H Shiono 2006 Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions Brain Res 1112 126 133 16884702 10.1016/j.brainres.2006.07.003 1:CAS:528:DC%2BD28Xps1Cksb8%3D (Pubitemid 44344618)
41. L Mignon WA Wolf 2007 Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease Psychopharmacology 192 49 59 17265149 10.1007/s00213-006- 0680-0 1:CAS:528:DC%2BD2sXkslWgs7c%3D (Pubitemid 46673886)
42. MJ Millan L Seguin A Gobert D Cussac M Brocco 2004 The role of dopamine D-3 compared with D-2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats Psychopharmacology 174 341 357 14985929 10.1007/s00213-003-1770-x 1:CAS:528:DC%2BD2cXls1antr8%3D (Pubitemid 39044292)
43. T Müller H Russ 2006 Levodopa, motor fluctuations and dyskinesia in Parkinson's disease Expert Opin Pharmacol 7 1715 1730 10.1517/14656566.7.13.1715
44. A Nadjar CR Gerfen E Bezard 2009 Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol 87 1 9 18938208 10.1016/j.pneurobio.2008.09.013 1:CAS:528: DC%2BD1MXmvVartw%3D%3D
45. CW Olanow P Damier CG Goetz T Mueller J Nutt O Rascol A Serbanescu F Deckers H Russ 2004 Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study) Clin Neuropharmacol 27 58 62 15252265 10.1097/00002826-200403000-00003 1:CAS:528:DC%2BD2cXks1Sgtr8%3D (Pubitemid 38569176)
46. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates, 3rd edn. Academic Press, New York
47. TA Pugsley MD Davis HC Akunne RG MacKenzie YH Shih G Damsma H Wikstrom SZ Whetzel LM Georgic LW Cooke SB Demattos AE Corbin SA Glase LD Wise D Dijkstra TG Heffner 1995 Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907 J Pharmacol Exp Ther 275 1355 1366 8531103 1:CAS:528:DyaK28XhvVyrtA%3D%3D (Pubitemid 26130641)
48. D Rylander M Parent SS O'Sullivan S Dovero AJ Lees E Bezard L Descarries MA Cenci 2010 Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Ann Neurol 68 619 628 20882603 10.1002/ana.22097 1:CAS:528:DC%2BC3cXhsFOnsrnE
49. F Sautel N Griffon P Sokoloff JC Schwartz C Launay P Simon J Costentin A Schoenfelder F Garrido A Mann CG Wermuth 1995 Nafadotride, a potent preferential dopamine D-3 receptor antagonist, activates locomotion in rodents J Pharmacol Exp Ther 275 1239 1246 8531087 1:CAS:528:DyaK28XhvVyksg%3D%3D (Pubitemid 26130635)
50. J Srinivasan WJ Schmidt 2004 The effect of the α2-adrenoreceptor antagonist idazoxin against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action? Naunyn Schmiedeberg's Arch Pharmacol 369 629 638 10.1007/s00210-004-0929-2 1:CAS:528:DC%2BD2cXks1KmtLc%3D (Pubitemid 38823995)
51. K Svensson A Carlsson N Waters 1994 Locomotor inhibition by the D-3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release J Neural Transm (Gen Sect) 95 71 74 10.1007/BF01283032 1:CAS:528:DyaK2cXjtFKnsbY%3D
52. U Ungerstedt GW Arburthnott 1970 Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions in the nigrostriatal dopamine system Brain Res 24 485 493 5494536 10.1016/0006-8993(70)90187-3 1:STN:280:DyaE3M%2Fotl2msA%3D%3D
53. NP Visanji MJ Millan JM Brotchie 2006 Actions at sites other than D-3 receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats Exp Neurol 202 85 92 16814282 10.1016/j.expneurol.2006. 05.016 1:CAS:528:DC%2BD28XpslSmtLc%3D (Pubitemid 44362988)
54. BY Zeng MM Iravani MJ Jackson S Rose A Parent P Jenner 2010 Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia Neurobiol Dis 40 599 607 20713157 10.1016/j.nbd.2010.08.004 1:CAS:528:DC%2BC3cXhtlSnurjP